Read More
Investigational drug may offer new treatment option for patients with lung and kidney cancer
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer.
Read More
>>Hollywood's Exotic Secret For Healthy Weight Loss
Read More
Subscribe to:
Post Comments (Atom)
0 Response to "Investigational drug may offer new treatment option for patients with lung and kidney cancer"
Post a Comment